|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Characterization of HULC, a Novel Gene With Striking Up-Regulation in Hepatocellular Carcinoma, as Noncoding RNA显示文摘 | Katrin Panzitt Marisa M.O. Tschernatsch Christian Guelly Tarek Moustafa Martin Stradner Heimo M. Strohmaier Charles R. Buck Helmut Denk Renée Schroeder Michael Trauner Kurt Zatloukal | 2007 | Gastroenterology2007，，1： | 4 |
| 2 | Dual roles of p62/SQSTM1 in the injury and recovery phases of acetaminophen-induced liver injury in mice显示文摘Acetaminophen(APAP)overdose can induce liver injury and is the most frequent cause of acute liver failure in the United States.We investigated the role of p62/SQSTM1(referred to as p62)in APAP-induced liver injury(AILI)in mice.We found that the hepatic protein levels of p62 dramatically increased at 24 h after APAP treatment,which was inversely correlated with the hepatic levels of APAPadducts.APAP also activated mTOR at 24 h,which is associated with increased cell proliferation.In contrast,p62 knockout(KO)mice showed increased hepatic levels of APAP-adducts detected by a specific antibody using Western blot analysis but decreased mTOR activation and cell proliferation with aggravated liver injury at 24 h after APAP treatment.Surprisingly,p62 KO mice recovered from AILI whereas the wild-type mice still sustained liver injury at 48 h.We found increased number of infiltrated macrophages in p62 KO mice that were accompanied with decreased hepatic von Willebrand factor(VWF)and platelet aggregation,which are associated with increased cell proliferation and improved liver injury at 48 h after APAP treatment.Our data indicate that p62 inhibits the late injury phase of AILI by increasing autophagic selective removal of APAP-adducts and mitochondria but impairs the recovery phase of AILI likely by enhancing hepatic blood coagulation. | Hui Qian Qingyun Bai Xiao Yang Jephte Y.Akakpo Lili Ji Li Yang Thomas Rulicke Kurt Zatloukal Hartmut Jaeschke Hong-Min Ni Wen-Xing Ding | 2021 | Acta Pharmaceutica Sinica B2021，11，12： | 4 |
| 3 | Cytokeratin 8 protects from hepatotoxicity and its ratio to cytokeratln 18 determines the ability of hepatocytes to form mallory bodies显示文摘 | ZATLOUKAL K STUMPTNER C LEHNER M | 2000 | Am J Pathol2000，156，4： | 1 |
| 4 | Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non small cell lung cancer: a randomized study 显示文摘 | Zatloukal P Petruzelka L Zemanova M | 2004 | Lung Cancer2004，46，1： | 1 |
| 5 | Phase III trial of cispl-atin plus gemcitabine with either placebo or bevacizumab asfirst-line therapy for nonsquamous non-small-cell lung cancer:Avail显示文摘 | Reck M von Pawel J Zatloukal P | 2009 | J Clin Oncol2009，27，8： | 1 |
| 6 | Final safety results of BO17704(A-VAiL):a phase III randomized study of first-line bevacizumab(BV)and cisplatin/gemcitabine(CG)in patients(pts)with ad-vanced or recurrent nonsquamous non-small cell lung cancer(NSCLC)显示文摘 | Hirsh V Ramlau R von Pawel J Zatloukal P Vera G Leighl N Mezger J Archer V Reck M | 2009 | J Clin Oncol2009，，： | 1 |
| 7 | PhaseⅢtrial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-smallcell lung cancer:AVAil显示文摘 | Reck M von Pawel J Zatloukal P | 2009 | J Clin Oncol2009，27，8： | 1 |
| 8 | A multicenter interna-tional randomized phaseⅢstudy comparing Cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease显示文摘 | Zatloukal P Cardenal F Szozesna A | 2010 | Ann Oncol2010，12，9： | 1 |
| 9 | miR-29a suppresses tristetraprolin,which is a regulator of epithelial polarity and metastasis显示文摘 | GEBESHUBER C A ZATLOUKAL K MARTINEZ J | 2009 | EMBO Rep2009，10，4： | 1 |
| 10 | Gemcitabine plus cis- platin vs gemcitabine plus carboplatin in stage Ⅲ b or IV non -small cell lung cancer: a phase Ⅲ randomized trial 显示文摘 | Zatloukal P Petruzelka L Zemanova M | 2003 | Lung Cancer2003，41，3： | 1 |
| 11 | 3D modeling of filtrationprocess via polyurethane nanofiber based nonwoven filters pre-pared by electrospinning process显示文摘 | Sambaer W Zatloukal M Kimmer D | 2011 | Chem Eng Sci2011，66，4： | 1 |
| 12 | A multicenter internationalrandomized phaseⅢ study comparing Cisplatin in combination withIrinotecan or Etoposide in previously untreated small-cell lung can-cer patients with extensive disease显示文摘 | Zatloukal P Cardenal F Szczesna A | 2010 | Ann Oncol2010，12，9： | 1 |
| 13 | Overall survival with cispl- atin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAIL)显示文摘 | Reck M yon Pawel J Zatloukal P | 2010 | Ann Oncol2010，21，9： | 1 |
| 14 | PhaseⅢ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer:AVAil显示文摘 | Reck M von Pawel J Zatloukal P | | 0，，： | 1 |
| 15 | miR-29a suppresses tristet-raprolin,which is a regulator of epithelial polarity and metastasis显示文摘 | Gebeshuber CA Zatloukal K Martinez J | 2009 | EMBO Rep2009，10，4： | 1 |
| 16 | Gemcitabine in non-small-cell lung cancer显示文摘 | Manegold C Zatloukal P Krejcy k | 2000 | Invest New Drugs2000，18，1： | 1 |
| 17 | Gemcitabine in non-small cell lung cancer(NSCLC) 显示文摘 | Manegold C Zatloukal P Krejcy K | 2000 | Invest New Drugs2000，18，1： | 1 |
| 18 | Phase El trial of cispl-atin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil显示文摘 | Reck M von Pawel J Zatloukal P | 2009 | J Clin Oncol2009，27，8： | 1 |
| 19 | miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis 显示文摘 | Gebeshuber CA Zatloukal K Martinez J | 2009 | EMBO Rep2009，10，： | 1 |
| 20 | Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study 显示文摘 | Zatloukal P Petruzelka L Zenmnova M | 2004 | Lung Cancer2004，46，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员